EFNS guidelines for the molecular diagnosis of neurogenetic disorders: Motoneuron, peripheral nerve and muscle disorders

J. M. Burgunder, L. Schöls, J. Baets, P. Andersen, T. Gasser, Z. Szolnoki, B. Fontaine, C. Van Broeckhoven, S. Di Donato, P. De Jonghe, T. Lynch, C. Mariotti, A. Spinazzola, S. J. Tabrizi, C. Tallaksen, M. Zeviani, H. F. Harbo, J. Finsterer

Research output: Article

32 Citations (Scopus)

Abstract

Objectives: These EFNS guidelines on the molecular diagnosis of motoneuron disorders, neuropathies and myopathies are designed to summarize the possibilities and limitations of molecular genetic techniques and to provide diagnostic criteria for deciding when a molecular diagnostic work-up is indicated.Search strategy: To collect data about planning, conditions and performance of molecular diagnosis of these disorders, a literature search in various electronic databases was carried out and original papers, meta-analyses, review papers and guideline recommendations reviewed.Results: The best level of evidence for genetic testing recommendation (B) can be found for the disorders with specific presentations, including familial amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy, Charcot-Marie-Tooth 1A, myotonic dystrophy and Duchenne muscular dystrophy. For a number of less common disorders, a precise description of the phenotype, including the use of immunologic methods in the case of myopathies, is considered as good clinical practice to guide molecular genetic testing.Conclusion: These guidelines are provisional and the future availability of molecular-genetic epidemiological data about the neurogenetic disorders under discussion in this article will allow improved recommendation with an increased level of evidence.

Original languageEnglish
Pages (from-to)207-217
Number of pages11
JournalEuropean Journal of Neurology
Volume18
Issue number2
DOIs
Publication statusPublished - febr. 2011

Fingerprint

Motor Neurons
Muscular Diseases
Peripheral Nerves
Molecular Biology
Genetic Testing
Guidelines
Atrophic Muscular Disorders
Genetic Techniques
Myotonic Dystrophy
Duchenne Muscular Dystrophy
Molecular Pathology
Meta-Analysis
Tooth
Databases
Phenotype

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

EFNS guidelines for the molecular diagnosis of neurogenetic disorders : Motoneuron, peripheral nerve and muscle disorders. / Burgunder, J. M.; Schöls, L.; Baets, J.; Andersen, P.; Gasser, T.; Szolnoki, Z.; Fontaine, B.; Van Broeckhoven, C.; Di Donato, S.; De Jonghe, P.; Lynch, T.; Mariotti, C.; Spinazzola, A.; Tabrizi, S. J.; Tallaksen, C.; Zeviani, M.; Harbo, H. F.; Finsterer, J.

In: European Journal of Neurology, Vol. 18, No. 2, 02.2011, p. 207-217.

Research output: Article

Burgunder, JM, Schöls, L, Baets, J, Andersen, P, Gasser, T, Szolnoki, Z, Fontaine, B, Van Broeckhoven, C, Di Donato, S, De Jonghe, P, Lynch, T, Mariotti, C, Spinazzola, A, Tabrizi, SJ, Tallaksen, C, Zeviani, M, Harbo, HF & Finsterer, J 2011, 'EFNS guidelines for the molecular diagnosis of neurogenetic disorders: Motoneuron, peripheral nerve and muscle disorders', European Journal of Neurology, vol. 18, no. 2, pp. 207-217. https://doi.org/10.1111/j.1468-1331.2010.03069.x
Burgunder, J. M. ; Schöls, L. ; Baets, J. ; Andersen, P. ; Gasser, T. ; Szolnoki, Z. ; Fontaine, B. ; Van Broeckhoven, C. ; Di Donato, S. ; De Jonghe, P. ; Lynch, T. ; Mariotti, C. ; Spinazzola, A. ; Tabrizi, S. J. ; Tallaksen, C. ; Zeviani, M. ; Harbo, H. F. ; Finsterer, J. / EFNS guidelines for the molecular diagnosis of neurogenetic disorders : Motoneuron, peripheral nerve and muscle disorders. In: European Journal of Neurology. 2011 ; Vol. 18, No. 2. pp. 207-217.
@article{11c29276e37546dc80338990a80ce2f6,
title = "EFNS guidelines for the molecular diagnosis of neurogenetic disorders: Motoneuron, peripheral nerve and muscle disorders",
abstract = "Objectives: These EFNS guidelines on the molecular diagnosis of motoneuron disorders, neuropathies and myopathies are designed to summarize the possibilities and limitations of molecular genetic techniques and to provide diagnostic criteria for deciding when a molecular diagnostic work-up is indicated.Search strategy: To collect data about planning, conditions and performance of molecular diagnosis of these disorders, a literature search in various electronic databases was carried out and original papers, meta-analyses, review papers and guideline recommendations reviewed.Results: The best level of evidence for genetic testing recommendation (B) can be found for the disorders with specific presentations, including familial amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy, Charcot-Marie-Tooth 1A, myotonic dystrophy and Duchenne muscular dystrophy. For a number of less common disorders, a precise description of the phenotype, including the use of immunologic methods in the case of myopathies, is considered as good clinical practice to guide molecular genetic testing.Conclusion: These guidelines are provisional and the future availability of molecular-genetic epidemiological data about the neurogenetic disorders under discussion in this article will allow improved recommendation with an increased level of evidence.",
keywords = "Amyotrophic lateral sclerosis, EFNS task force, Molecular diagnosis, Myopathy, Neurogenetics, Polyneuropathy, Spinal muscular atrophy",
author = "Burgunder, {J. M.} and L. Sch{\"o}ls and J. Baets and P. Andersen and T. Gasser and Z. Szolnoki and B. Fontaine and {Van Broeckhoven}, C. and {Di Donato}, S. and {De Jonghe}, P. and T. Lynch and C. Mariotti and A. Spinazzola and Tabrizi, {S. J.} and C. Tallaksen and M. Zeviani and Harbo, {H. F.} and J. Finsterer",
year = "2011",
month = "2",
doi = "10.1111/j.1468-1331.2010.03069.x",
language = "English",
volume = "18",
pages = "207--217",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - EFNS guidelines for the molecular diagnosis of neurogenetic disorders

T2 - Motoneuron, peripheral nerve and muscle disorders

AU - Burgunder, J. M.

AU - Schöls, L.

AU - Baets, J.

AU - Andersen, P.

AU - Gasser, T.

AU - Szolnoki, Z.

AU - Fontaine, B.

AU - Van Broeckhoven, C.

AU - Di Donato, S.

AU - De Jonghe, P.

AU - Lynch, T.

AU - Mariotti, C.

AU - Spinazzola, A.

AU - Tabrizi, S. J.

AU - Tallaksen, C.

AU - Zeviani, M.

AU - Harbo, H. F.

AU - Finsterer, J.

PY - 2011/2

Y1 - 2011/2

N2 - Objectives: These EFNS guidelines on the molecular diagnosis of motoneuron disorders, neuropathies and myopathies are designed to summarize the possibilities and limitations of molecular genetic techniques and to provide diagnostic criteria for deciding when a molecular diagnostic work-up is indicated.Search strategy: To collect data about planning, conditions and performance of molecular diagnosis of these disorders, a literature search in various electronic databases was carried out and original papers, meta-analyses, review papers and guideline recommendations reviewed.Results: The best level of evidence for genetic testing recommendation (B) can be found for the disorders with specific presentations, including familial amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy, Charcot-Marie-Tooth 1A, myotonic dystrophy and Duchenne muscular dystrophy. For a number of less common disorders, a precise description of the phenotype, including the use of immunologic methods in the case of myopathies, is considered as good clinical practice to guide molecular genetic testing.Conclusion: These guidelines are provisional and the future availability of molecular-genetic epidemiological data about the neurogenetic disorders under discussion in this article will allow improved recommendation with an increased level of evidence.

AB - Objectives: These EFNS guidelines on the molecular diagnosis of motoneuron disorders, neuropathies and myopathies are designed to summarize the possibilities and limitations of molecular genetic techniques and to provide diagnostic criteria for deciding when a molecular diagnostic work-up is indicated.Search strategy: To collect data about planning, conditions and performance of molecular diagnosis of these disorders, a literature search in various electronic databases was carried out and original papers, meta-analyses, review papers and guideline recommendations reviewed.Results: The best level of evidence for genetic testing recommendation (B) can be found for the disorders with specific presentations, including familial amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy, Charcot-Marie-Tooth 1A, myotonic dystrophy and Duchenne muscular dystrophy. For a number of less common disorders, a precise description of the phenotype, including the use of immunologic methods in the case of myopathies, is considered as good clinical practice to guide molecular genetic testing.Conclusion: These guidelines are provisional and the future availability of molecular-genetic epidemiological data about the neurogenetic disorders under discussion in this article will allow improved recommendation with an increased level of evidence.

KW - Amyotrophic lateral sclerosis

KW - EFNS task force

KW - Molecular diagnosis

KW - Myopathy

KW - Neurogenetics

KW - Polyneuropathy

KW - Spinal muscular atrophy

UR - http://www.scopus.com/inward/record.url?scp=78751491533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751491533&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2010.03069.x

DO - 10.1111/j.1468-1331.2010.03069.x

M3 - Article

C2 - 20500522

AN - SCOPUS:78751491533

VL - 18

SP - 207

EP - 217

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 2

ER -